Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.01.002Source: DataRank Database

An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma is a research paper published in Clinical Lymphoma Myeloma & Leukemia (2024). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 1.81)OA: greenTopics (31)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Sikander Ailawadhi ORCID,Gabriel Búrbano,Patrick O’Brien ORCID,Francis K. Buadi ORCID,Suzanne R. Hayman

Live enrichment

PubMed:38220589 PMC:PMC11045312 OpenAlex:https://openalex.org/W4390636935

National Cancer Institute

Grant: R01CA254961

NCI NIH HHS

Grant: P50 CA186781

National Institutes of Health

FWCI

1.81

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11045312/pdf/nihms-1959218.pdf

publisherhttps://api.elsevier.com/content/article/PII:S2152265024000193?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2152265024000193?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11045312

Fields of Study

Multiple Myeloma Research and TreatmentsMetabolism, Diabetes, and CancerPI3K/AKT/mTOR signaling in cancer

MeSH Terms

BortezomibAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMetforminMiddle AgedMultiple MyelomaNeoplasm Recurrence, LocalNelfinavir

Keywords

MedicineBortezomibNelfinavirRefractory (planetary science)MetforminMultiple myelomaOncologyInternal medicineLenalidomidePharmacologyVirologyHuman immunodeficiency virus (HIV)InsulinmyelomaRelapsed And Refractory

Sustainable Development Goals

SDG 0: Good health and well-being

An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma

FAIR Checklist

Authors (8)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)